ASPP2增强结肠癌HCT116细胞对奥沙利铂的化疗敏感性

为研究ASPP2对奥沙利铂诱导的结肠癌细胞系HCT116 p53+/+(野生型)凋亡及周期的影响.利用ASPP2（rAd-ASPP2）及p53腺病毒（rAd-p53）感染HCT116 p53+/+细胞,经奥沙利铂50 μmol/L诱导细胞凋亡及周期改变.Western印迹检测ASPP2及p53的表达水平;MTT法检测ASPP2腺病毒对奥沙利铂诱导的HCT116细胞活性的影响;Calcein/PI吸收试验检测细胞凋亡情况;流式细胞术分析细胞周期分布. 结果显示,ASPP2、p53共同过表达,或者ASPP2单独过表达均能增强奥沙利铂诱导的HCT116 p53+/+细胞增殖抑制,以及S期抑制并伴有细胞凋亡水平的升高;而无奥沙利铂诱导时,ASPP2对HCT116 p53+/+细胞的活性、细胞周期及细胞凋亡水平的影响无统计学意义. 上述结果表明,ASPP2能够增强奥沙利铂诱导HCT116 p53+/+细胞的增殖抑制、细胞周期抑制和细胞凋亡.     

EGCG对人结肠癌HT-29细胞凋亡的影响以及对MMP-2,RECK的调节作用

目的：观察表没食子儿茶素没食子酸酯（Epigallaocatechin-3-gallate,EGCG）对人结肠癌HT-29细胞增殖和凋亡的影响,并探讨其对MMP-2,RECK的调节作用。方法：体外培养人结肠癌HT-29细胞,MTT比色法检测EGCG对HT-29细胞的生长抑制作用;Histone/DNA ELISA检测细胞凋亡;FITC标记Annexin-V/PI双染流式细胞术分析凋亡细胞百分率;Western Blot和RT-PCR方法检测EGCG对MMP-2,RECK蛋白和mRNA表达的影响。结果：EGCG呈浓度和时间依赖性抑制HT-29细胞的增殖,并且增加HT-29细胞Histone/DNA碎片的渗漏;EGCG诱导HT-29细胞凋亡百分率增高;EGCG抑制MMP-2蛋白和mRNA的表达,促进RECK蛋白和mRNA的表达。结论：EGCG抑制人结肠癌HT-29细胞的增殖,促进其凋亡,并且呈浓度和时间依赖性;其作用机制可能与其下调MMP-2蛋白和mRNA的表达、上调RECK蛋白和mRNA的表达有关。     

EGCG 对人结肠癌HT-29 细胞凋亡的影响以及对MMP-2，RECK 的 调节作用

目的:观察表没食子儿茶素没食子酸酯(Epigallaocatechin-3-gallate,EGCG)对人结肠癌HT-29细胞增殖和凋亡的影响,并探讨其对MMP-2,RECK的调节作用。方法:体外培养人结肠癌HT-29细胞,MTT比色法检测EGCG对HT-29细胞的生长抑制作用;Histone/DNA ELISA检测细胞凋亡;FITC标记Annexin-V/PI双染流式细胞术分析凋亡细胞百分率;Western Blot和RT-PCR方法检测EGCG对MMP-2,RECK蛋白和mRNA表达的影响。结果:EGCG呈浓度和时间依赖性抑制HT-29细胞的增殖,并且增加HT-29细胞Histone/DNA碎片的渗漏;EGCG诱导HT-29细胞凋亡百分率增高;EGCG抑制MMP-2蛋白和mRNA的表达,促进RECK蛋白和mRNA的表达。结论:EGCG抑制人结肠癌HT-29细胞的增殖,促进其凋亡,并且呈浓度和时间依赖性;其作用机制可能与其下调MMP-2蛋白和mRNA的表达、上调RECK蛋白和mRNA的表达有关。     

缺氧微环境SIRT1亚细胞定位对结直肠癌细胞凋亡的影响及其机制研究

目的:探究缺氧微环境SIRT1亚细胞定位对结直肠癌细胞凋亡的影响及其分子机制。方法:将编码过表达野生型SIRT1以及核定位序列(nuclear localization sequence,NLS)突变型SIRT1(SIRT1NLSmt)的慢病毒载体转染人类结肠癌HCT116细胞株,经嘌呤霉素筛选获得稳定过表达野生型SIRT1细胞株(LV-SIRT1细胞)和细胞质定位的NLS突变型SIRT1细胞株(LV-SIRT1NLSmt细胞),通过观察慢病毒载体编码的SIRT1-GFP融合蛋白的荧光定位,明确稳定转染细胞中外源性SIRT1的亚细胞定位。利用real-time PCR、Western blot法对分离提取的核-质蛋白进行检测,证实外源性SIRT1的表达和亚细胞定位情况。利用CCK-8细胞毒性实验、流式细胞术检测和TUNEL染色比较缺氧(1%O2)处理前后LV-SIRT1和LV-SIRT1NLSmt细胞存活或凋亡情况,Western blot法检测凋亡相关蛋白p53、ac-p53(K382)、Bcl-2、Bax、caspase-3和cleaved caspase-3表达水平。结果:Western blot、real-time PCR和免疫荧光染色结果显示稳定转染细胞均存在外源性SIRT1的过表达,NLS突变可导致SIRT1NLSmt富集于细胞质中;与亲本细胞HCT116和LV-SIRT1NLSmt细胞相比,LV-SIRT1细胞对缺氧的耐受能力最差、细胞凋亡水平最高,凋亡相关蛋白p53、Bax、caspase-3、cleaved caspase-3表达水平显著升高,ac-p53(K382)和Bcl-2表达水平显著下降,且LV-SIRT1细胞的胞核ac-p53下降最为显著。结论:在缺氧微环境中,细胞核定位的SIRT1通过影响p53的去乙酰化水平促进结直肠癌细胞凋亡。     

JIB-04通过调控细胞周期蛋白抑制结肠癌细胞增殖

已有报道显示,组蛋白去甲基化酶抑制剂JIB-04(Jumonji histone demethylase inihibitor,JIB-04)抑制肿瘤的发生发展,但其具体作用机制仍不清楚。本研究以结肠癌细胞HCT116和HT29为对象,探讨组蛋白去甲基化酶抑制剂JIB-04对结肠癌细胞增殖的影响,并阐述其作用机制。MTT和平板克隆形成实验显示,JIB-04以浓度和时间依赖的方式降低HCT116和HT29细胞的增殖能力,半数抑制浓度分别为661.7 nmol/L及226.1 nmol/L,细胞克隆数也明显减少。qRT-PCR和Western印迹结果证明,与未经JIB-04处理的HCT116和HT29细胞比较,细胞周期蛋白D1(cyclinD1)、细胞周期蛋白E1(cyclinE1)的mRNA水平和CDK4、CDK6及细胞周期蛋白D1的蛋白质水平有不同程度的降低,同时CDK抑制剂p21的蛋白质水平分别上调约1.99倍和2.37倍。检测凋亡相关因子发现,在HCT116和HT29细胞中,p53、胱天蛋白酶3、胱天蛋白酶9、Bax、JNK及PUMA的mRNA及蛋白质水平均降低。机制研究显示,JIB-04使组蛋白赖氨酸特异性去甲基化酶1(LSD1)的mRNA水平分别下调约56.8%和75.5%,其蛋白质水平下调约27.12%和15.32%。本研究结果表明,JIB-04可改变组蛋白赖氨酸特异性去甲基化酶LSD1的活性,调控细胞周期蛋白及相关因子在mRNA和蛋白质水平的表达,同时诱导凋亡蛋白质发生改变,从而抑制结肠癌细胞增殖和凋亡。     

Ku70乙酰化介导TSA诱导的结肠癌细胞凋亡

目的:探讨组蛋白去乙酰化酶抑制剂(HDI)trichostatin A(TSA)对Ku70的乙酰化及其在TSA诱导结肠癌细胞凋亡中的作用。方法:以TSA处理结肠癌细胞HCT116和HT29细胞,采用免疫沉淀结合Western blot检测TSA对Ku70乙酰化的作用,流式细胞术检测TSA诱导的细胞凋亡,Western blot检测凋亡相关蛋白Bax和细胞色素c(cytochrom c)的转位和表达。结果:TSA可引起结肠癌HCT116和HT29细胞Ku70乙酰化,并与凋亡密切相关,与对照组相比,HCT116凋亡率(P=0.007)和HT29细胞凋亡率(P=0.005)均显著增高,免疫共沉淀检测到TSA处理细胞后,Bax和Ku70之间的相互作用减弱,表明TSA引起的乙酰化促进Bax从Bax-Ku70复合物中释放,Western blot结果显示TSA促进Bax由胞浆向线粒体转位,同时促进cytochrom c由线粒体向胞浆转位。结论:Ku70乙酰化作用介导了TSA诱导的结肠癌细胞凋亡。     

双歧杆菌脂磷壁酸对结肠癌细胞抑制增殖和促凋亡的研究

目的 探讨双歧杆菌脂磷壁酸(lipoteichoic acid,LTA)抑制人类结肠癌细胞株HCT116细胞增殖和促进凋亡情况.方法 培养结肠癌细胞株HCT116和提取双歧杆菌LTA;实验分为4组,即LTA低剂量组(20 μg/mL)、中剂量(60 μg/mL)、高剂量(100μg/mL)和HCT116对照组(Control);用四甲基偶氮唑蓝法(MTT)检测LTA对结肠癌细胞增殖的抑制率,流式细胞仪检测LTA对结肠癌细胞周期分布变化和凋亡率,免疫组化分析bcl-2、Cytochrome C和NF-kBp65含量变化,RT-PCR检测TLR2mRNA和TLR4m RNA的表达.结果 MTT法测得LTA各组对结肠癌细胞HCT116均具有较好的抑制(P＜0.01);流式细胞仪检得G0/G1期细胞显著增多(P＜0.01),而G2和S期细胞减少(P＜0.05),细胞凋亡率增加(P＜0.05);免疫组化分析IOD/Area值,bcl-2和NF-kBp65表达显著下调,Cytochrome C显著上升(P＜0.05);RT-PCR测得TLR2 mRNA和TLR4 mRNA的表达均上升(P＜0.05).结论 LTA具有明显的抑制结肠癌细胞增殖和促进凋亡作用,为研制高效、无毒的新型抗结肠癌药物奠定一定的基础.     

人野生型p53基因增强5-FU对大肠癌化疗敏感性的分子生物学机制

为了探讨人野生型p53（wt-p53）基因增强大肠癌细胞化疗敏感性的分子生物学机制,将携带wt p53基因的质粒分别转染两种p53基因突变的人大肠癌细胞系HT-29及SW620,分析细胞中p53及细胞周期蛋白D1（cyclin D1）蛋白的表达水平;将化疗药物5 氟尿嘧啶（5-fluorouracil,5-FU）以不同浓度、不同时间分别作用于HT-29及SW620细胞,另外将已转染wt-p53基因的大肠癌细胞用5-FU进行诱导,Western印迹分析上述干预条件下细胞中p53蛋白及细胞周期蛋白D1表达水平的变化;流式细胞术检测wt p53基因联合5-FU组及对照组中细胞凋亡的改变情况.结果表明,wt-p53基因能增加癌细胞中细胞周期蛋白D1的表达,与wt-p53基因呈剂量依赖性关系;5-FU则降低其蛋白表达,与5-FU呈时间和剂量依赖性关系,而5-FU所致的细胞周期蛋白D1表达水平的降低在细胞预先转染了wt- p53基因时会被抑制;wt-p53基因与5-FU联合使用能提高大肠癌细胞凋亡率.结果提示,wt-p53基因可提高大肠癌细胞中细胞周期蛋白D1的表达水平,并抑制5-FU所致的细胞周期蛋白D1降解,从而提高大肠癌细胞对化疗药物5-FU的敏感性.     

p53在蓝莓花青素诱导Lovo细胞凋亡中的作用

[目的]研究蓝莓花青素(BA)对人结肠癌Lovo细胞增殖及凋亡的影响,分析凋亡相关基因—p53基因mRNA和蛋白表达的变化。[方法]分别用浓度为50μg/ml、100μg/ml、200μg/ml的BA处理结肠癌Lovo细胞24h,采用MTT法、免疫荧光法和Real-time PCR法和免疫细胞组织化学分析BA对Lovo细胞增殖、细胞凋亡、p53 mRNA和蛋白表达的影响。[结果]BA呈剂量依赖的方式抑制Lovo细胞增殖;能诱导细胞发生晚期凋亡;与对照组相比,不同浓度BA处理后p53基因mRNA表达水平分别上调0.602、0.697、0.541倍(P0.05),但BA不同剂量组间并无明显的差异(P0.05);免疫细胞组化结果表明随着BA浓度的增加,p53表达增强。[结论]BA可以诱导结肠癌Lovo细胞发生晚期凋亡,p53基因mRNA表达上调,但与BA的浓度无相关性。     

硫化砷对人结肠癌细胞株HCT116生长及迁移能力的影响

目的:研究硫化砷对人结肠癌细胞株HCT116迁移能力的影响及其作用机制.方法:以HCT116细胞为研究对象,通过MTT法观察硫化砷对肿瘤细胞活性及增殖能力的影响,通过划痕实验观察硫化砷处理后细胞的迁移能力.Western B1ot、Real-time PCR检测硫化砷处理前后细胞内E-钙粘素、P53、Notch1蛋白的表达及相应mRNA水平的变化.结果:硫化砷对HCT116细胞有抑制增殖的作用,此作用随着剂量的增加而增强.选取无毒剂量的硫化砷(1 μM)处理HCT116细胞24h后,细胞的迁移能力降低了52.00％±7.55％.Western Blot及Real-time PCR结果显示,硫化砷处理后,HCT116细胞内的E-钙粘素蛋白水平及mRNA水平均明显升高,P53蛋白水平增高,但对Notch1蛋白及mRNA水平无明显影响.结论:一定剂量范围的硫化砷能抑制HCT116细胞增殖,并能降低其迁移能力.硫化砷降低HCT116细胞的迁移能力,其机制可能是通过上调P53蛋白的水平,从而增高E-钙粘素的表达实现的.     

The relative contribution of pro-apoptotic p53 target genes in the triggering of apoptosis following DNA damage in vitro and in vivo

The p53 pathway displays a large degree of redundancy in the expression of a number of pro-apoptotic mechanisms following DNA damage that, among others, involves increased expression of several pro-apoptotic genes through transactivation. Spatial and temporal cellular contexts contribute to the complexity of the regulation of apoptosis, hence different genes may show a cell- and tissue-dependent specificity with regard to the regulation of cell death and act in concert or show redundancy with one and another. We used siRNA technology to assess the effect of multiple ablations of documented pro-apoptotic p53 target genes (PPG) in the colorectal cancer cell line HCT116 and generated mice deficient in both of the extrinsic and intrinsic PPGs genes Dr5 and Puma following treatment with chemotherapeutics and ionizing radiation. DR5, Fas, Bax, Bad, Puma and Bnip3L were induced by 5-FU and adriamycin (ADR) in HCT116 cells in a p53-dependent manner. The resulting caspase 3/7 activity in HCT116 cells following treatment were suppressed by ablated expression of the PPGs in the extrinsic as well as the intrinsic pathway. To our surprise, knocking-down any of the PPGs concomitantly with DR5 did not further inhibit caspase 3/7 activity whereas inhibiting DR5-expression in HCT116Bax knockdown (kd) and HCT116Fas kd did, suggesting that these genes act downstream or in synergy with DR5. This was supported by our in vivo observations, since Puma and Dr5 were equally efficient in protecting cells of the spleen from sub-lethal radiation-induced apoptosis but less effective compared with irradiated p53^−/− mice. To our surprise, Dr5^−/−; Puma^−/− mice did not show additive protection from radiation-induced apoptosis in any of the investigated organs. Our data indicates that the intrinsic pathway may rely on extrinsic signals to promote cell death in a cell- and tissue-dependent manner following DNA damage. Furthermore, p53 must rely on mechanisms independent of DR5 and PUMA to initiate apoptosis following γ-radiation in the spleen and thymus in vivo.Key words: p53, KILLER/DR5, PUMA, apoptosis, DNA damage     

Aciculatin Induces p53-Dependent Apoptosis via MDM2 Depletion in Human Cancer Cells In Vitro and In Vivo

Aciculatin, a natural compound extracted from the medicinal herb Chrysopogon aciculatus, shows potent anti-cancer potency. This study is the first to prove that aciculatin induces cell death in human cancer cells and HCT116 mouse xenografts due to G1 arrest and subsequent apoptosis. The primary reason for cell cycle arrest and cell death was p53 accumulation followed by increased p21 level, dephosphorylation of Rb protein, PUMA expression, and induction of apoptotic signals such as cleavage of caspase-9, caspase-3, and PARP. We demonstrated that p53 allele-null (-/-) (p53-KO) HCT116 cells were more resistant to aciculatin than cells with wild-type p53 (+/+). The same result was achieved by knocking down p53 with siRNA in p53 wild-type cells, indicating that p53 plays a crucial role in aciculatin-induced apoptosis. Although DNA damage is the most common event leading to p53 activation, we found only weak evidence of DNA damage after aciculatin treatment. Interestingly, the aciculatin-induced downregulation of MDM2, an important negative regulator of p53, contributed to p53 accumulation. The anti-cancer activity and importance of p53 after aciculatin treatment were also confirmed in the HCT116 xenograft models. Collectively, these results indicate that aciculatin treatment induces cell cycle arrest and apoptosis via inhibition of MDM2 expression, thereby inducing p53 accumulation without significant DNA damage and genome toxicity.     

Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells

Combined-modality treatment has improved the outcome in cases of various solid tumors, and radiosensitizers are used to enhance the radiotherapeutic efficiency. Rosiglitazone, a synthetic ligand of peroxisome proliferator-activated receptors γ used in the treatment of type-2 diabetes, has been shown to reduce tumor growth and metastasis in human cancer cells, and may have the potential to be used as a radiosensitizer in radiotherapy for human colorectal cancer cells. In this study, rosiglitazone treatment significantly reduced the cell viability of p53-wild type HCT116 cells but not p53-mutant HT-29 cells. Interestingly, rosiglitazone pretreatment enhanced radiosensitivity in p53-mutant HT-29 cells but not HCT116 cells, and prolonged radiation-induced G₂/M arrest and enhanced radiation-induced cell growth inhibition in HT-29 cells. Pretreatment with rosiglitazone also suppressed radiation-induced H2AX phosphorylation in response to DNA damage and AKT activation for cell survival; on the contrary, rosiglitazone pretreatment enhanced radiation-induced caspase-8, -9, and -3 activation and PARP cleavage in HT-29 cells. In addition, pretreatment with a pan-caspase inhibitor, zVAD-fmk, attenuated the levels of caspase-3 activation and PARP cleavage in radiation-exposed cancer cells in combination with rosiglitazone pretreatment. Our results provide proof for the first time that rosiglitazone suppresses radiation-induced survival signals and DNA damage response, and enhances the radiation-induced apoptosis signaling cascade. These findings can assist in the development of rosiglitazone as a novel radiosensitizer.     

Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells

Chemoresistance is a key cause of treatment failure in colon cancer. MiR-22 is a tumor-suppressing microRNA. To explore whether miR-22 is an important player in the development of chemoresistance in colon cancer, we overexpressed miR-22 and subsequently tested its role in cell proliferation, apoptosis, survival, and associated signaling in p53-mutated HT-29 and HCT-15 cells, and p53 wild-type HCT-116 cells. We further investigated the role of miR-22 on cytotoxicity of paclitaxel in both the p53-mutated and p53 wild-type colon cancer cells. Results showed that HT-29 and HCT-15 cells were resistant to paclitaxel-induced cytotoxicity, which normally inhibits cell proliferation and survival, and induces apoptosis. Conversely, HCT-116 was relatively sensitive to the cytotoxicity of paclitaxel. Overexpression of miR-22 significantly decreased cell proliferation and survival, and induced cell apoptosis in the p53-mutated colon cancer cells, but played no role in the p53 wild-type cells. Importantly, miR-22 overexpression enhanced the cytotoxic role of paclitaxel in p53-mutated HT-29 and HCT-15 cells, but not in p53 wild-type HCT-116 cell. We further demonstrated that the tumor-suppressive role of miR-22 in p53-mutated colon cancer cells was mediated by upregulating PTEN expression, which negatively regulated Akt phosphorylation at Ser(473) and MTDH expression, and subsequently increased Bax and active caspase-3 levels. Our study is the first to identify the tumor-suppressive role of miR-22 and its associated signaling in the p53-mutated colon cancer cells and highlighted the chemosensitive role of miR-22.     

Regulation of p53 stability and function in HCT116 colon cancer cells

We have used a lentiviral vector to stably express p53 at a physiological level in p53 knockout HCT116 cells. Cells transduced with wild type p53 responded to genotoxic stress by stabilizing p53 and expressing p53 target genes. The reconstituted cells underwent G(1) arrest or apoptosis appropriately depending on the type of stress, albeit less efficiently than parental wild type cells. Compared with cells expressing exogenous wild type p53, the apoptotic response to 5-fluorouracil (5FU) was >50% reduced in cells expressing S15A or S20A mutant p53, and even more reduced by combined mutation of serines 6, 9, 15, 20, 33, and 37 (N6A). Among a panel of p53 target genes tested by quantitative PCR, the gene showing the largest defect in induction by 5FU was BBC3 (PUMA), which was induced 4-fold by wild type p53 and 2-fold by the N6A mutant. Mutation of N-terminal phosphorylation sites did not prevent p53 stabilization by doxorubicin or 5FU. MDM2 silencing by RNA interference activated p53 target gene expression in normal fibroblasts but not in HCT116 cells, and exogenous p53 could be stabilized in HCT116 knockout cells despite combined mutation of p53 phosphorylation sites and silencing of MDM2 expression. The MDM2 feedback loop is thus defective, and other mechanisms must exist to regulate p53 stability and function in this widely used tumor cell line.     

Curcumin induced apoptosis is mediated through oxidative stress in mutated p53 and wild type p53 colon adenocarcinoma cell lines

Curcumin has anti‐oxidant, anti‐cancer and anti‐carcinogen property. Our laboratory had previously reported that, curcumin treatment induces reactive oxygen species (ROS) generation in HT‐29 cell line, an effect contradictory to its anti‐oxidant property. This study evaluates the role of p53 in curcumin mediated ROS generation and cell death. Curcumin induced ROS was determined by 2’,7’‐dichlorofluorescein and apoptosis by Hoechst33342/PI staining in HT‐29 and HCT‐116 cell lines. ROS generation occurs within 1 hour of 40 µM curcumin treatment and a reduction was observed by third hour in HCT‐116 insinuating p53 involvement. N‐acetyl cysteine (NAC) pre‐treatment effectively quenched ROS and inhibited membrane potential loss in HT‐29, but less effective in HCT‐116. Mitochondrial membrane potential loss is evident with 10 and 40 µM curcumin in HCT‐116 and at 40 µM curcumin in HT‐29. Total p53 protein level increase was observed by 24 hours in HCT‐116 upon NAC pre‐treatment. Our results indicate that curcumin induces ROS mediated cell death in colon adenocarcinoma cell lines and may be mediated via p53.